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BACKGROUND: Treatment trials for Irritable Bowel Syndrome (IBS) commonly report 
satisfactory relief of symptoms as an outcome measure at the end of a trial. It is unclear what 
predicts a response to this multidimensional construct. 
AIMS: (1) Assess if the following primary independent variables predict satisfactory relief of 
bowel symptoms: patient reported effectiveness of treatment, patient report severity of side 
effects, and patient satisfaction with initial physician visit. (2) Determine if these independent 
variables differ among patients taking prescription versus non-prescription medications for IBS 
relief. (3) Determine if satisfactory relief is predicted by baseline scores on the Irritable Bowel 
Syndrome Symptom Severity Scale (IBS-SS) or the Brief Symptom Inventory (BSI). ( 4) Test if 
the independent variables predict satisfaction with treatment. 
METHODS: A total of 835 patients (78% females, average age 52 yr) who had a medical 
diagnosis ofiBS and satisfied Rome II criteria, were recruited from Group Health Cooperative of 
Puget Sound. The initial questionnaire assessed baseline symptom severity (IBS-SS) and 
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psychological distress (BSI). The follow-up questionnaire, administered after 6 months, assessed 
responses to the satisfactory relief outcome measured on a binary scale, satisfaction with 
treatment outcome measured on an ordinal scale, and responses to patient reported effectiveness 
of treatment, patient report severity of side effects, and patient satisfaction with initial physician 
visit. 
RESULTS: Greater patient reported treatment effectiveness predicted satisfactory relief for 
prescription drug users (OR= 3.1) and nonprescription drug users (OR= 2.3). Lesser side effect 
severity to prescription drugs was a statistically significant predictor of satisfactory relief for 
prescription drugs (OR= 0.65) but not nonprescription drugs. Patient satisfaction with initial 
physician visit had a negligible predictive value for the satisfactory relief outcome after adjusting 
for other independent variables. Responses to the secondary outcome, satisfaction with treatment 
measured on an ordinal scale, were largely congruent with satisfactory relief for all primary 
variables tested. Neither baseline psychological distress nor baseline symptom severity 
significantly predicted satisfactory relief after multivariable adjustment, although the results 
suggest that a larger sample may show significant trends. 
CONCLUSIONS: These data from an observational study suggest that patient's perceptions of 
drug effectiveness and side effect severity with prescription medications are significant 
predictors of satisfactory relief, while physician-patient interaction does not significantly predict 
satisfactory relief. These results may help in the future design of clinical trials for IBS. 
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Introduction: 
Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder (FGID) with a 
complex pathophysiologic basis but largely diagnosed by exclusion of organic disease. IBS is 
commonly encountered in general medical practices with prevalence rates in the United States 
estimated to be 10- 15%1. Known physiologic determinants include colonic dysmotility, 
intestinal hypersensitivity, changes in bacterial flora, mucosal immune dysregulation, and 
alteration of the CNS-ENS pathway. Using symptom-based criteria, the Rome III committee 
define IBS to include pain associated with a change in bowel habits, and suggests that it cliffers 
from other FGIDs including functional diarrhea and functional constipation2 . 
IBS Treatment Efficacy 
The FDA has declared a preference that investigators state, a priori, what defines a 
responder to treatment in clinical trials ofiBS3. A responder should be defined by a change in 
symptoms that gives clear evidence that a patient has experienced clinically meaningful benefit 
from treatment. IBS studies should report the proportion of subjects who are considered 
responders. However, controversy exists over what constitutes a clinically meaningful 
improvement for IBS relief, and studies have used multiple definitions to identify a responder 
including responses to symptom-based questionnaires, health-related quality oflife instruments, 
health care costs, and global measurements that use non-specific outcome targets such as 
responses to "satisfactory relief' or "adequate relief,"4"8. A consensus on IBS endpoints has 
proven difficult given the diversity of endpoints employed in trials, use of both clinician and 
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patient-centered responses, and measurement of responses on various response scales including 
categorical scales, visual analogue scales, numerical scales, and global assessment scales2' 9. 
The latest recommendation by the Rome III committee recognizes that two global 
measures of symptomatology, "adequate relief' and "satisfactory relief," are the current standard 
for assessing efficacy in clinical trials of IBS. In addition, a validated symptom questionnaire, 
like the Irritable J:lowel Syndrome Symptom Severity Scale (IBS-SS), can serve as a primary 
outcome measure2• However, classifying an IBS patient as a responder in clinical trials has 
proved especially difficult for multiple reasons. By definition, IBS is a clinically diagnosed 
condition and no single biological marker exists.10 Moreover, few effective therapies are 
available or are robust, and thus responsiveness can only be assessed under subtherapeutic 
states4 . Since the disease is generally not fatal, conventional analytic methods, like survival 
analysis, are not applicable. 
The adequate relief endpoint has often been used as a global measure in assessing 
treatment efficacy. The FDA approved this outcome measure in testing alosetron for IBS relief11' 
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. The original wording was phrased, "In the past 7 days have you had adequate relief of your 
IBS pain and discomfort," and responses were a dichotomous yes/no answer. Similarly, 
satisfactory relief was used in treatment trials oftegaserod15' 16, and patients offered a yes/no 
response to the question, "Over the past week, do you consider that you have had satisfactory 
relief from your IBS symptoms." 
A recent FDA report entitled "Patient-Reported Outcome Measures: Use in Medical 
Product Development to Support Labeling Claims" describes proper validation of patient 
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reported measmes. Important properties of a well devised patient-reported outcome (PRO) 
instrument include the ability to reliably measme the concepts it was designed to assess 
(reliability), the ability to address all the relevant symptoms related to the disorder (content 
validity), the ability to generate comparable results from a similar but independent instrument 
(construct validity), the ability to detect a change in symptoms when one has occurred 
(responsiveness), and the ability to detect the smallest difference between treatment groups that 
is considered clinically important (interpretability/. 
Although the psychometric properties of global assessment endpoints ofiBS have been 
studied to a certain extent4• 10• 17, the validity of these endpoints has been in question recently. A 
study by Whitehead and colleagues investigated if baseline symptom severity (classified as mild, 
moderate, or severe by a validated questionnaire) is linked to the probability of reporting 
satisfactory relief. The authors concluded that satisfactory relief was confounded by baseline 
symptom severity. Although patients with mild symptoms at baseline were more likely to report 
satisfactory relief, they were less likely to have a large reduction in IBS symptom severity 
compared to patients with severe symptoms at baseline 18 . A recent review challenged these 
results citing an unpublished abstract of a phase II trial. Although the study showed similar 
response to adequate relief among patients with mild, moderate, and severe pain at baseline, the 
review did not report how baseline severity was measured (and likely not with a validated 
questionnaire like the IBS-SS since pain was the only symptom measured) nor did it report a 
response to adequate relief in a way that is currently used in IBS trials9• Bijkerk and colleagues 
recommend the adequate relief question when measuring global symptomatology in IBS studies, 
6 
but identified specific psychometric and methodological properties requiring further validation 
including reliability and generalizability to the primary care population 4. 
Determining a minimum clinically important difference between responders and 
nonresponders has also been a challenge in IBS clinical trials that use global assessment 
endpoints. Corriziari and colleagues recommend defining a responder to include a 50% 
improvement in the global assessment measure19• While this definition has shown to be able to 
establish efficacy in some clinical trials, further validation is needed to determine if a 50% 
improvement is the most clinically appropriate threshold. An additional issue is properly 
classifYing patients as responders and nonresponders over time. Clinical trials of tegaserod 
measured satisfactory relief at one week intervals and labeled patients as responders or non-
responders during each interval. At the end of the trial, patients were classified as overall 
responders if they reported satisfactory relief for at least 50% of the weeks. Reviewers suggested 
that more statistical modeling and analyses are needed to establish thresholds for response over 
time2. Supporters of the adequate relief endpoint state that this measure allows patient to 
integrate all relevant symptoms ofiBS related to their own reference standard9• However the 
adequate relief question commonly used in clinical trials only asks about relief from IBS pain 
and discomfort and excludes other critical symptoms including change in the frequency and 
consistency of stools. The current wording of this global assessment tool could fail to recognize 
efficacy of treatments that improve bowel function. 
IBS Treatment Side Effects 
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Tolerability is an important issue in tbe evaluation of investigational treatment for IBS. 
IBS is a heterogeneous condition often subdivided into constipation predominant, diarrhea 
predominant, and alternating predominant subtypes. Treatments often target one specific 
subgroup for relief of symptoms (e.g. promotility therapy for constipation-predominant disease) 
and thus could adversely impact other patient populations (e.g. diarrhea predominant disease). 
Limited published data exists on the tolerability of pharmacologic agents used in tbe treatment of 
IBS compared to measures of efficacy. A recent systematic review concluded that there is 
insufficient evidence to assess the impact of side effects of newer IBS agents as well as older 
therapies including non-prescription medications20. Furthermore, many of the therapies used are 
non-prescription medications that have not been evaluated for IBS in large trials. 
Surveys have shown a correlation between level of dissatisfaction with IBS medications 
and treatment side effects21 • However, given the similarities between IBS symptoms and side 
effects of the medications given to treat IBS symptoms, such as abdominal cramps, bloating, and 
diarrhea, difficulties arise in distinguishing between lack of efficacy and presence of side effects 
in treatment trials. In a survey by tbe International Foundation for Functional Gastrointestinal 
Disorders (IFFGD), over 50% of patients reported some degree of side effects related to 
prescription medication. Patients reporting side effects with treatment were also more likely to be 
dissatisfied with the remedy and suffer adverse events including hospitalizations, emergency 
room visits, and missed days at work and school22• However, one limitation of the IFFGD survey 
was that it analyzed patients normally excluded from clinical trials of IBS including those with 
inflammatory bowel disease, diverticulitis, and other organic diseases. 
8 
Doctor-Patient Relationship 
Psychosocial variables are important determinants.of global wellbeing, and a strong 
doctor-patient relationship is an important aspect of successful treatment of IBS23 . A physician 
approach that addresses a patient's psychological and social status, adopts a positive and 
encouraging attitude that is patient -centered, addresses patient concerns, and involves the 
appropriate prescription of medications and referrals to mental health professionals are all 
identified as ways to help patients cope with IBS symptoms24. Furthermore, a positive physician-
patient interaction has been shown to be associated with fewer return visits for IBS25. However, 
IBS patients have reported an unsympathetic attitude from their medical provide~6, and other 
studies have characterized doctors as often being intolerant towards their IBS patients27 . 
The patient-physician relationship is a difficult dimension to study because the quality of 
a medical visit is difficult to assess, details of the initial observation are often not recorded in 
medical charts, and patients who seek therapy for IBS have different characteristics from those 
who don't seek therapy including greater severity of disease and higher rates of anxiety and 
depression28. A systematic review by Dhaliwal and colleagues explored the doctor-patient 
interaction and consequences of IBS. They concluded that IBS patients in the primary care 
setting commonly experience negative attitudes and dissatisfaction in the interaction with their 
physicians, but due to limitations in the review, this may not be generalizable to all IBS patients. 
The study recognized a need for further understanding of the doctor-patient relationship in order 
to better meet and manage a patient's needs29. 
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Study Aims 
The patient-reported outcomes used in clinical trials attempt to capture attitudes, 
behaviors, and events associated with IBS treatment. A patient's perspective of how well a 
treatment works, the severity of side effects associated with a treatment, and level of satisfaction 
with the physician may determine if a patient is a responder or nonresponder for global endpoints 
in clinical trials ofiBS. The Rome III guidelines identifies a number of priorities for future 
research in the design of treatment trials for IBS that include: examining the influence of disease 
modifiers (predictors) on outcome measures, examining the impact of baseline observations on 
treatment response, further validating "satisfactory relief' as a primary endpoint, and further 
evaluating the definitions of a treatment responder2 • 
Determining predictors of treatment satisfaction may be useful in further validating 
current endpoints used in IBS trials as well as identifying potential gaps in the current design of 
treatment trials. If determinants of treatment satisfaction vary by class of medication, this may 
suggest the need to refine the outcome measures depending on the type of intervention being 
tested. Identifying factors that predict lower rates of treatment satisfaction may also uncover 
patient groups in need of additional resources and attention. 
The aims of this study were (1) to assess if the following primary independent variables 
predict satisfactory relief of bowel symptoms: patient reported effectiveness of treatment, patient 
reported severity of side effects, and patient satisfaction with the initial physician visit; (2) to 
determine if these independent variables differ among patients taking prescription versus non-
prescription medication for IBS relief; (3) to determine if satisfactory relief is predicted by 
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baseline scores on the Irritable Bowel Syndrome Symptom Severity Scale (IBS-SS) or the Brief 
Symptom Inventory (BSI) scale that measures psychological symptoms; (4) to test if the 
independent variables predict satisfaction with treatment, a novel outcome measure that 
measures response on an ordinal scale. 
Methods: 
Setting: 
This survey was conducted between December 4, 2001 and September 12, 2002 at the 
Group Health Cooperative ofPuget Sound (GHC). This large health maintenance organization 
serves 400,000 members in Seattle, Washington. The demographics of this patient population are 
similar to the demographics of the Seattle area, except for less representation of the highest and 
lowest income groups30. In comparison to the rest of the United States, GHC and the Seattle area 
have a higher proportion of Asians and a lower proportion of African Americans and Hispanics. 
The demographic makeup of the GHC membership is otherwise similar to the United States 
population. 
Subjects: 
Investigators prospectively screened all patient encounter forms submitted by 353 
primary care physicians and 16 gastroenterologists to identifY patients with a clinical diagnosis 
ofiBS (564.0), abdominal pain (789.X), constipation (564.0), and diarrhea (787.91). Patients 
from these groups who fulfilled the Rome II criteria for IBS31 were included in the analysis. 
Patients also had to be aged 18-75, enrolled in GHC for at least 1 year, and have no treatment 
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record for ulcerative colitis or Crohn's disease. Sampling was stratified with the goal of enrolling 
500 patients with IBS from primary care clinics and 300 patients with IBS from gastroenterology 
clinics. Among the 1770 patients who participated in the study, the final analysis included a total 
of 835 patients meeting Rome II criteria for IBS with no diagnosis of organic disease. 
Design: 
Subjects who met eligibility criteria were mailed an invitation to participate, an informed 
consent statement, and the initial questionnaires within 1 week of receipt of their clinical 
encounter forms by the administrative offices of GHC. In the invitation to participate, subjects 
were told to telephone or write the survey team at GHC if they chose not to participate. They 
were also informed that if they neither returned the questionnaires nor refused to participate, they 
would be telephoned after approximately 2 weeks to remind them to complete the questionnaires. 
At least six attempts were made to contact each participant. 
Participants who returned the initial set of questionnaires were re-contacted 6 months 
later to collect updated information and to complete follow-up questionnaires. Further details of 
the recruitment process are summarized in Figure I. A 10 dollar incentive was offered for 
completing the initial survey and a second $10 incentive for completing the follow-up survey. 
The survey was initially designed to describe usual medical care for IBS32, and the type of 
treatment prescribed was decided by each individual patient's primary care physician or 
gastroenterologist. This study was reviewed and approved by the institutional boards of GHC, 
the University of Washington, and the University ofNorth Carolina at Chapel Hill. 
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Questionnaires: 
The primary outcome measure assessed patient reported satisfactory relief with a yes/no 
response to the question: "In the past 7 days, have you had satisfactory relief of your bowel 
symptoms?" Bowel symptoms were defined in a footnote to include abdominal pain and 
discomfort, bloating, constipation, and diarrhea. Separate analyses were performed for 
prescription users and nonprescription users. A second, novel, outcome measure assessed patient 
response to satisfaction with treatment. The question asked: "How satisfied or dissatisfied are 
you with the relief you are experiencing from the prescription, non-prescription, herbal remedies 
or other/alternative treatments you are taking for your bowel symptoms (abdominal pain and 
discomfort, bloating, constipation, diarrhea)?" Responses to prescription and non-prescription 
medication were assessed on the following 5-point Likert scale: I = extremely dissatisfied; 2 = a 
little dissatisfied; 3 = somewhat satisfied; 4 = very satisfied; 5 = extremely satisfied. Rating of 
herbal remedies and alternative treatments are not included in this report. 
The first primary independent variable tested was patient-reported effectiveness of usual 
treatment. 1bis potential predictor variable was assessed in the follow-up survey, six months 
following the index visit, with the following question: "To what extent has the prescription, non-
prescription, herbal remedies, or other/alternative treatments you have taken been effective in 
relieving your bowel symptoms (abdominal pain and discomfort, bloating, constipation, 
diarrhea)?" Only responses to prescription and non-prescription medication were assessed on a 
5-point Likert scale: I =not at all effective; 2 =a little effective; 3 =somewhat effective; 4 = 
very effective; 5 = extremely effective. 
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The second primary independent variable tested was patient-reported side-effect severity 
of usual treatment. Patients responded to the following question in the follow-up survey: "Please 
tell us whether you experienced any side effects from these treatments?" Responses for the 
following 9 categories oftreatment were categorized as prescription treatment (anti-spasmodic 
drugs, anti-diarrheal drugs, and psychotropic medications) or non-prescription treatment 
(laxatives, stool softeners, fiber supplements, and OTC drugs for gas relief, anti-diarrhea, and 
pain). Responses were assessed on a 4-point Likert scale: 1 =no side effects; 2 =mild side 
effects; 3 =moderate side effects; 4 =severe side effects. 
The third primary independent variable tested was patients' response to satisfaction with 
their initial physician visit. The initial survey asked the following question using a numerical 
scale: "How satisfied were you with the care you received at your last visit? Rate your 
satisfaction from 0% (very dissatisfied) to I 00% (very satisfied). A rating of 50% would mean 
that you were neither dissatisfied nor satisfied with the clinic visit but are waiting to see." The 
"last visit" refers to the index visit with either the primary care physician or gastroenterologist. 
The initial survey also included the following integrative symptom questionnaires: (1) 
Rome questionnaire to determine if subjects met Rome II criteria for IBS31 • (2) The Irritable 
Bowel Symptom Severity Scale (IBS-SS) to assess overall severity of IBS symptoms. (3) The 
Brief Symptom Inventory-18 (BSI) to assess psychological symptoms. Additional questionnaires 
which are not included in this study were also administered; see prior report32• 
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IBS-SS 
The impact of baseline symptom severity on patient-reported satisfaction with treatment 
was assessed using the IBS-SS scale. This validated questionnaire contains five questions which 
address (1) typical severity of abdominal pain over the last 10 days, (2) frequency of abdominal 
pain, (3) severity of abdominal distension, ( 4) dissatisfaction with bowel habits, and (5) impact 
ofiBS symptoms on everyday activities. All questions contribute equally to the total score, 
which ranges from 0 to 500. 1n accordance with previously validated cutoffs33, patients were 
categorized as having mild baseline symptom severity if they reported scores below 175, 
moderate symptom severity if reported scores were between 175 and 300, and severe symptom 
severity if reported scores were greater than 300. 
The IBS-SS was cited as the only validated integrative symptom questionnaire by the 
Rome III committee2. It has been tested in hypnosis trials34• 35 and in a study of usual care for 
IBS32 . Furthermore, the IBS-SS was not confounded by initial symptom severity when used to 
define a responder as having a 50% reduction in symptoms18• However, a review by Camilleri 
and colleagues recommends further validation ofthe psychometric properties and scoring 
algorithm of this scale specifically related to internal consistency, construct validity, and factor 
structure. They point out that the IBS-SS gives equal weight to all five items comprising the 
scale, and thus may not accurately capture the clinical heterogeneity of each patient's disease 
process9• To further validate this scale and assess for confounding effects, we tested if baseline 
scores on the IBS-SS predicted response to the outcome measures. 
15 
The impact of psychological distress and psychiatric illness on patient-reported 
satisfaction with treatment was assessed using the BSI-18 scale. The full BSI measures distress 
with 53 items that contain nine subscales and 3 global scales36• The BSI-18 is an abridged scale 
that measures the primary dimensions of psychological distress including somatization, 
depression, and anxiety. It is written at a 6th grade level and requires 5 to 7 minutes to complete. 
For analysis, the raw scores were first transformed to T -scores to allow males and females to be 
pooled together. Patients with T -scores of 63 or higher were classified as abnormal, i.e., 
reflective of clinically significant psychological distress37. 
Data Analysis: 
Qualitative analysis involved a comparison of the three primary independent variables 
(patient reported severity of treatment side effect, patient reported effectiveness of treatment 
effectiveness, and patient satisfaction with initial physician visit) with the ordinal dependent 
variable (patient satisfaction with treatment) using bar graphs. Separate bar graphs were shown 
for prescription and nonprescription drug users, and median values were calculated for responses 
to the primary independent variables measured on an ordinal scale. The physician satisfaction 
rating was measured on a continuous scale (from 0- 1 00), and scores were divided equally into 
quintiles when comparing this independent variable to the primary endpoint, satisfaction with 
treatment, on the bar graphs. 
A nonparametric correlation coefficient, Kendall tau-b, was computed to test correlations 
between (a) the primary independent variables and the outcome measures and between (b) 
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baseline scores on the integrative symptom questionnaires (IBS-SS and BSI) and the outcome 
measures. Separate correlations were performed for responses to satisfaction with prescription 
and nonprescription treatment, and p values less than 0.05 were considered statistically 
significant. 
A binary logistic regression analysis was used to test the hypothesis that the primary 
independent variables and baseline symptom scores predict responses to patient reported 
satisfactory relief. The 1" model tested if the primary independent variables predicted responses 
to satisfactory relief of symptoms after adjusting for demographic characteristics. Demographic 
characteristics included age, gender, education status (dichotomized as college graduate and 
greater vs. less than college graduate), and race (Caucasian vs. non-Caucasian). The 2nd model 
tested if the primary independent variables predicted responses to satisfactory relief of symptoms 
after adjusting for baseline symptom scores on the IBS-SS (categorized as mild, moderate, and 
severe) and BSI (treated as a continuous variable) scales. 
The secondary outcome measure, ordinal response to patient satisfaction with treatment, 
was evaluated with an ordinal logistic regression analysis. A similar modeling strategy was 
performed for the secondary outcome measure as was performed for the binary satisfactory relief 
of symptoms outcome. The 1st model tested whether the primary independent variables 
predicted satisfaction with treatment after adjusting for demographic characteristics, and the 2nd 
model tested whether the primary independent variables predicted satisfaction with treatment 
after adjusting for baseline symptom scores. 
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For all regression models, separate analyses were carried for users of prescription 
treatment and nonprescription treatment. All analyses were conducted with Stata Statistical 
Software: Release 9.0 (College Station, TX), and results from logistic regression models were 
reported using odds ratios and 95% confidence intervals. 
Results: 
Patient Characteristics 
Table 1 shows the demographic characteristics of participants, median baseline scores on 
the integrated symptom questionnaires, and median satisfaction rating with the index physician 
visit. The study participants were largely white and female. Asians and blacks were the next 
most commonly represented minority groups, comprising 4% of the study population each. 
A similar number of patients self reported using prescription and nonprescription 
medication .. In contrast to non-prescription users, prescription users appeared to have greater 
symptom severity at baseline (IBS-SS score of277.7 vs. 257.3) and were less likely to be college 
graduates (40.5% vs. 44.7%). Otherwise the two groups appeared similar. No statistical 
comparisons of demographic characteristics were made between groups in Table 1 because some 
patients reported taking both prescription and nonprescription medications. 
Among the 835 patients diagnosed with IBS by Rome II criteria, 215 had missing 
responses for the outcome measure, patient satisfaction with prescription or nonprescription 
treatment (Table 1 ). Although subjects with missing responses were more likely to be Hispanic 
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and non-college graduates, they otherwise appeared similar to those using prescription and 
nonprescription drugs that responded to the outcome measure. 
Treatment Side Effect Severity 
Table 2 shows a statistically significant and negative correlation between side effect 
severity and satisfactory relief of symptoms for users of prescription and nonprescription 
medications. As side effect severity increased, satisfactory relief of symptoms decreased. Similar 
correlation coefficients were seen between side effect severity and the secondary outcome 
measure, satisfaction with treatment measured by an ordinal scale, for prescription and 
nonprescription users (Table 3). 
Multivariate regression analysis was performed to determine if severity of side effects to 
treatment predict satisfactory relief after adjusting for potential covariates. Table 4 shows that the 
odds of reporting satisfactory relief of symptoms decreased as patients experienced greater side 
effect severity with prescription drugs after adjusting for patient characteristics (Table 4, Model 
I) or baseline symptom severity (Table 4, Model II). Similarly, for the second outcome measure, 
patients with greater side effect severity to prescription drugs were less likely to report 
satisfaction with treatment after adjusting for patient characteristics (Table 6, Model I) or 
baseline symptom severity (Table 6, Model II). 
Different trends were noted for side effect severity to nonprescription drugs, compared to 
prescription drugs, for the outcome measures. As side effect severity with nonprescription drugs 
increased, the odds of reporting satisfactory relief of symptoms decreased after adjusting for 
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patient characteristics (Table 5, Model I). However, side effect severity was no longer a 
statistically significant predictor of satisfactory relief after adjusting for baseline symptom 
severity (Table 5, Model II). In contrast, side effect severity remained a statistically significant 
predictor for the satisfaction with treatment outcome after adjusting for patient characteristics 
(Table 7, Model I) and baseline symptom severity (Table 7, Model II). 
Treatment Effectiveness 
Table 2 shows a positive and statistically significant correlation between treatment 
effectiveness and satisfactory relief of symptoms for users of prescription and nonprescription 
medications (Table 2). Similar correlation coefficients were seen between treatment 
effectiveness and the secondary outcome measure, satisfaction with treatment (Table 3). 
In Figures 2 and 3, bar graphs describe the median number of patients reporting 
satisfaction with treatment for categories of treatment effectiveness. The abscissa divides all 
patients into 5 groups based on their reports of treatment effectiveness, and the ordinate shows 
median satisfaction with treatment for the various subgroups. The bar graphs support the positive 
trends suggested by the correlations: as patients report increasing effectiveness of treatment, 
satisfaction with treatment increases. The trend appears to be similar for prescription and 
nonprescription treatments. 
The odds ratios reported in the logistic regression models for prescription treatment 
effectiveness (Table 4) confirmed this variable as a strong predictor of satisfactory relief. After 
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adjusting for patient characteristics (Table 4, Model I) and baseline symptom severity (Table 4, 
Model II), the odds of reporting satisfactory relief ofiBS symptoms increased as effectiveness of 
prescription medication increased. For the second outcome measure, effectiveness of prescription 
medications was a strong predictor of satisfaction with prescription treatment after adjusting for 
patient demographics (Table 6, Model I) and baseline symptom severity (Table 6, Model II). 
Increased effectiveness of nonprescription medication was also a strong predictor of 
satisfactory relief. As patient reported increased effectiveness of nonprescription treatment, odds 
of reporting satisfactory relief of IBS symptoms increased significantly after adjusting for patient 
characteristics (Table 5, Model I) and baseline symptom severity (Table 5, Model II). Similarly, 
patient reported effectiveness of nonprescription drugs was a strong predictor of the secondary 
outcome measure, satisfaction with treatment, after adjusting for patient characteristics (Table 7, 
Model I) and baseline symptom severity (Table 7, Model II). 
Satisfaction with Physician Visit 
For both prescription and nonprescription users, the correlation between satisfaction with 
initial physician visit and satisfactory relief of IBS symptoms six months later were statistically 
significant and support a positive trend: as satisfaction scores with physician visit increased on a 
continuous scale, binary response to satisfactory relief of symptoms increased (Table 2). Similar 
correlation coefficients were seen between satisfaction with physician visit and the secondary 
outcome measure, satisfaction with prescription and nonprescription medications (Table 3). 
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In Figures 4 and 5, bar graphs describe the median number of patients reporting 
satisfaction with medications for categories of physician satisfaction. The abscissa divides 
prescription and nonprescription drug users into 5 equal quintiles based on the satisfaction rating 
with their physician. The ordinate shows median satisfaction with treatment for subgroups 
differing in physician satisfaction ratings. For prescription drug users, the bar graph (Figure 4) 
shows a positive trend that supports the correlation coefficient. However, patients in quintiles 
representing scores from 20 to 80 reported moderate levels of treatment satisfaction regardless of 
their physician visit. For nonprescription drug users, the bar graph suggests a relatively weak 
positive trend where patients report moderate levels of treatment satisfaction except those in the 
lowest quintile (Figure 5). 
Although the odds ratios for the initial satisfaction rating with physician visit and 
satisfactory relief of symptoms were statistically significant (Table 4 and 5), the point estimates 
were very close to one suggesting that the doctor visit had a negligible effect on any response to 
the outcome measure. Similarly, satisfaction with physician visit does appear to meaningfully 
contribute to a response to the secondary outcome measure, satisfaction with treatment (Table 6 
and 7), after adjusting for other independent variables, patient demographics, and baseline 
symptom scores. 
Baseline IBS-SS 
Lower baseline symptom severity (categorized as mild, moderate, and severe on the IBS-
SS) was correlated with satisfactory relief ofiBS symptoms on the binary scale (Table 2) and 
satisfaction with treatment on the ordinal scale (Table 3) for both users of prescription and 
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nonprescription medication. After adjusting for the three primary independent variables and 
baseline psychological distress (BSI), baseline symptom severity was not a statistically 
significant predictor of satisfactory relief ofiBS symptoms for prescription drug users (Table 4, 
Model II) or nonprescription drug users (Table 5, Model II). For the secondary outcome 
measure, lower baseline symptom severity was a statistically significant predictor of satisfaction 
with prescription treatment (Table 6, Model II) but not nonprescription treatment (Table 7, 
Model II). 
Baseline BSI 
Lower scores on the psychological distress scale, measured at baseline, were significantly 
correlated with satisfactory relief ofiBS symptoms (Table 2) and satisfaction with treatment 
(Table 3). However, after adjusting for the primary independent variables and baseline symptom 
scores, lower baseline scores on the BSI did not predict satisfactory relief of IBS symptoms for 
users of prescription drugs (Table 4, Model II) or nonprescription drugs (Table 5, Model II). 
Similarly, lower baseline psychological distress was not a significant predictor of satisfaction 
with prescription (Table 6, Model II) or nonprescription treatment (Table 7, Model II) after 
adjusting for other variables. 
Discussion: 
Global endpoints that ask patients whether they received satisfactory or adequate relief of 
IBS symptoms are considered the current standard for assessing efficacy ofiBS treatment in 
clinical trials. However, classifYing a patient as a responder in clinical trials has proven difficult, 
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and the use of global endpoints has been a topic of controversy in recent literature. Recognizing 
this, members of the Rome III committee recommended further validation of satisfactory and 
adequate relief outcome measures during clinical trials. Specific suggestions for future research 
included determining predictors of response to IBS symptom relief, evaluating the impact of 
baseline symptoms on treatment response, and further characterizing the multidimensional 
construct of satisfactory and adequate relief'. 
In an effort to address these recommendations, we hypothesized that a patient's rating of 
treatment effectiveness, severity of side effects with medication, and satisfaction with the 
physician visit predicts response to satisfactory relief of IBS symptoms. Based on results from a 
previous study, we also hypothesized that lower baseline symptom severity would predict 
satisfactory relief, but baseline psychological distress would not have a significant effect on this 
outcome measure18 . 
Predictive Value of the Primarv Independent Variables: 
The data presented in this study shows that when patients with a Rome diagnosis ofiBS 
believe their treatment is effective, they are much more likely to report satisfactory relief of their 
IBS symptoms after 6 months. The odds ratios reported in Table 4 and Table 5 shows that (1) 
patient reported treatment effectiveness is the strongest predictor of satisfactory relief compared 
to any other independent variable tested and (2) the predictive value of treatment effectiveness is 
stronger for prescription medication (OR- 3.0) compared to nonprescription medication (OR-
2. 0). This second finding implies that high effectiveness ratings of prescription drugs are more 
likely to predict satisfactory relief with IBS symptoms compared to similar ratings of 
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nonprescription drugs, and this is concordant with previous survey results22. The effectiveness of 
herbal remedies and alternative treatments was not assessed in this study. 
After adjustment for correlations among the independent variables, the regression 
analyses (Table 4-7) show that severity of side effects to IBS treatment is the next strongest 
predictor of response to satisfactory relief of IBS symptoms. The odds ratios reported in Table 4 
are for categories of side effect severity. For every one level increase on the ordinal scale of side 
effect severity to prescription drugs (e.g. moderate side effects 7 severe side effects), patients 
have about half the odds (OR- 0.65) of reporting satisfactory relief with IBS symptoms. 
Compared to prescription drugs, side effect severity with nonprescription drugs is a weaker 
predictor of satisfactory relief and becomes statistically non-significant after adjusting for other 
variables (Table 5, Model II). The differences between prescription and nonprescription drugs 
are logical as side effects of prescription drugs are associated with greater levels of distress and 
adverse events22 and thus require a physician consultation. Several possible explanations may 
exist as to why severity of side effects to prescription drugs, but not nonprescription drugs, 
predicts satisfactory relief. First, given the similarities between side effects of treatment and 
symptoms of IBS, patients taking prescription drugs may have greater severity of disease 
compared to those taking nonprescription drugs. By adjusting for baseline symptoms scores, we 
hoped to control for some of this effect. Second, a severe side effect to a prescription drug may 
differ compared to a severe side effect to a nonprescription drug. However, specific side effects 
to medication were not addressed in this study. 
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Previous studies suggest that the doctor-patient interaction can be beneficial or 
detrimental depending on the physician's approach to the patient's disease process. The simple 
correlations shown in Tables 2 and 3 support this association. However, after adjusting for the 
correlations among variables by multivariate regression analysis (Tables 4-7), patient satisfaction 
was no longer a significant predictor of treatment satisfaction. Although the odds ratios for 
prescription and nonprescription drug users are statistically significant, the point estimates are 
close to one and therefore probably should be considered negligible. It is important to note that 
all three primary predictor variables were adjusted for each other in the multivariable logistic 
regression analyses. Therefore, while a positive patient-physician interaction alone may predict 
satisfaction with IBS relief, the joint effect of treatment effectiveness and side effect severity 
may no longer make the patient-physician interaction a significant predictor of satisfactory relie£ 
Additionally, all patient satisfaction scores were pooled together in the analysis regardless of 
whether the provider was a primary care physician or gastroenterologist. Therefore, the impact of 
the doctor-patient relationship on satisfactory relief may differ based on provider type, but this 
potential difference was not assessed in the analysis. 
Validation of Satisfactory Relief with aN ovel Endpoint 
We also tested if treatment effectiveness, side effect severity, and satisfaction with 
physician predicted response to a second, novel outcome measure, satisfaction with treatment 
measured on an ordinal scale. We found similar results from the ordinal logistic regression 
models using the satisfaction with treatment endpoint (Table 6 and 7) when compared to the 
binary logistic regression models using the satisfactory relief with symptoms endpoint (Table 4 
and 5). However, notable differences were observed. First, effectiveness of prescription and 
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nonprescription drugs is a much stronger predictor of satisfaction with treatment (OR- 1 0-20) 
compared to satisfactory relief of IBS symptoms (OR- 2-3). Conceptually, effectiveness of 
treatment is more closely related to satisfaction with treatment than it is to satisfactory relief of 
symptoms and may be one reason to account for differences between endpoints. 
Second, lower severity of side effects to nonprescription drugs is a significant predictor 
of satisfaction with treatment (Table 7) but not a predictor of satisfactory relief ofiBS symptoms 
(Table 5, Model II). The choice of the response scale used may in part explain why side effect 
severity to nonprescription drugs is a statistically significant predictor of one endpoint and not 
the other. An advantage of measuring response on an ordinal scale, compared to a binary scale, is 
that it increases sensitivity and specificity due to a greater number of response options. 
Therefore, the binary scale may not be equipped to detect a statistically significant difference in 
yes/no responses to satisfactory relief based on severity of side effect to nonprescription drugs. 
However, it is important to note that these two endpoints distinctly differ (satisfaction with 
symptoms vs. satisfaction with treatment) and thus evaluating different concepts altogether. 
The use of a second, novel outcome measure lends construct validity and reliability to the 
results for the satisfactory relief endpoint. The FDA report on validation of PRO instruments 
recommends that the primary instrument show convergent results with a similar but independent 
secondary instrument38• Construct validity was demonstrated as results from satisfactory relief 
endpoint compared favorably with results from the satisfaction with treatment endpoint, a similar 
but independent measure. Confirmation with an ordinal scale measure also adds reliability due to 
the greater number of response options. 
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Baseline Symptom Severity 
A previous study reported that satisfactory relief is confounded with initial IBS symptom 
severity, and patients with lower baseline symptom severity were more likely to report 
satisfactory relief compared to patients with higher baseline symptom severity18 . Simple 
correlations (Table 2 and 3) are consistent with this earlier report. However, after adjustment for 
the correlations among variables by multivariate regression analysis, baseline symptom severity 
did not significantly predict satisfactory relief of symptoms for prescription (Table 4) or 
nonprescription (Table 5) drug users. Although the influence of baseline symptom severity on 
satisfactory relief is statistically non-significant in this study, the point estimates for the odds 
ratios for users of prescription drugs (OR= 0.636) support previously reported results. 
Furthermore, the relative proximity of the upper confidence limit to 1.0 suggests that lower 
baseline symptom severity may predict satisfactory relief in a larger sample size. Additionally, 
lower baseline symptom severity was a significant predictor of the secondary outcome measure, 
satisfaction with prescription treatment (Table 6, Model II). Increased sensitivity and specificity 
of this ordinal measure suggests a lack of power to detect a statistically significant difference for 
the binary satisfactory relief endpoint. Further confirmation with a clinical trial is needed. 
Baseline psychological distress, as measured by the BSI scale, does not predict satisfactory relief 
after adjusting for IBS symptom severity and the primary independent variables, and these 
I d . h . 18 resu ts are concor ant Wit a pnor report . 
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Limitations: 
Out of 835 patients in the final study analysis, there were 215 missing responses to the 
satisfactory relief outcome measure. From Table I, patients with missing responses appear more 
likely be Hispanic and have lower education status than non-missing responders. One possibility 
is that missing responders may not have understood wording of the instructions or scaling of the 
response options. Otherwise, patients with missing responses did not seem to systematically 
differ from patients with non-missing responses based on pertinent demographic and baseline 
characteristics. 
All concepts and domains measured in the study are based on patient-reported responses 
to outcome measures as well as to questionnaires assessing treatment effectiveness, side effect 
severity, and satisfaction ratings with physician visit. Any undue physical, emotional, or 
cognitive strain on patients can decrease the quality of reported data38 . Additionally, any degree 
of administrator burden including how questionnaires are distributed, administered, and analyzed 
can undermine the validity of results. However, the integrity of the questionnaires used in this 
study have been examined30 and results from the questionnaires have been published in prior 
reports18• 32. 
This study was not a clinical trial but an observational study of patients receiving usual 
medical care for IBS. As such, limitations are present given the study design including the way 
patients were selected to be in the study and the influence of factors, other than the independent 
variables identified, on the outcome measures. To minimize selection bias, we provided 
eligibility criteria consistent with recommendations by the Rome III committee on design on IBS 
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studies2, and included a flow diagram (Figure 1) explicitly stating how patients were emolled in 
the study and junctures where dropouts occurred. We recognize that satisfactory relief is a 
multidimensional construct, and responses to this outcome are predicted by variables other than 
those identified in this study. Furthermore results from this population of patients receiving 
treatment for IBS in an outpatient, managed care setting may not be generalizable to all IBS 
patients. However, we extended the generalizability of these results by including usual care 
given by primary care physicians and gastroenterologists, in contrast to other studies that report 
only one provider type. 
This study is the first to assess predictors of response to satisfactory relief of IBS 
symptoms. The results show that a patient's perception of drug effectiveness is a significant 
predictor of satisfactory relief, a commonly used endpoint in clinical trials ofiBS treatment. We 
also show that tolerability to prescription medication, but not nonprescription drugs, is an 
important predictor of treatment efficacy and that the initial patient -doctor interaction has little 
effect on satisfactory relief after adjusting for other variables. The results from this study may 
help in the future design of clinical trials ofiBS. 
30 
Figure 1. Flow diagram of recruitment 
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Table 1. Demographics of Sample 
Prescription Non-Prescription Missing Responses 
(n=323) (n=359) (n=215) 
Mean age, years 52.2 ± 14.4 52.0 ± 14.7 50.0 ± 15.4 
Gender: % female 78.6 79.1 72.9 
Race: % Caucasian 88.6 88.1 84.5 
Ethnicity: % Hispanic 3.3 3.3 7.3 
Education: % College 40.5 44.7 36.1 graduate or greater 
IBS-QOL: 
mean score 69.6 ± 20.6 72.7 ± 18.7 67.7 ± 22.3 
IBS-SS: 
mean score 277.7± 104.5 257.3 ± 104.1 264.1 ± 111.6 
BSI: 
mean T -score 55.5 ± 10.4 54.7±10.1 56.6 ± 10.5 
Satisfaction w/ index 66.1 ± 26.8 67.5 ± 26.3 66.0 ± 26.5 
visit 
32 
Table 2. Correlations between Binary Satisfactory Relief and Independent Variables 
Treatment Treatment Satisfaction Baseline Baseline 
with Effectiveness Side-Effects Physician Visit IBS-SS BSI 
Prescription Users: 0.4028 -0.1630 0.3036 -0.2449 -0.1250 
Satisfactory Relief (p < 0.0001) (p ~ 0.0039) (p < 0.0001) (p ~ 0.0002) (p ~ 0.0270) 
Nonprescription Users: 0.3201 -0.1701 0.2562 -0.2278 -0.1048 
Satisfactory Relief (p < 0.0001) (p ~ 0.0001) (p < 0.0001) (p < 0.0001) (p ~ 0.0272) 
(All correlat10ns performed With Kendall's tau-b) 
T bl 3 C a e l ti orre a ons btw e een Odi lSff: f "th T t t d I d r na a IS ac lOll WI reamen an n epen dent Variables 
Treatment Treatment Satisfaction Baseline Baseline 
Effectiveness Side-Effects with IBS-SS BSI 
Physician Visit 
Satisfaction with 0.7398 -0.1905 0.2329 -0.2675 -0.1882 
Prescription (p < 0.0001) (p ~ 0.0013) (p < 0.0001) (p < 0.0001) (p < 0.0001) 
Treatment 
Satisfaction with 0.6993 -0.1678 0.2066 -0.1685 -0.1160 
Non-Prescription (p < 0.0001) (p ~ 0.0009) (p < 0.0001) (p ~ 0.0005) (p ~ 0.0050) 
Treatment 
(All correlatwns performed With Kendall's tau-b) 
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Figure 3: Satisfaction with Treatment vs. Treatment Effectiveness (Nonprescription) 
34 
Figure 5: Satisfaction with Treatment vs. Physician Satisfaction (Nonprescription) 
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Adjusted Odds Ratios Comparing Binary Response to Satisfactory Relief with Independent 
Variables. 
T bl 4 P a e rescnptwn D U rug sers 
Independent Variable Odds Ratio Confidence 
Interval 
tModell 
Patient Reported Treatment 
3.080 2.103-4.511 Effectiveness (5-point ordinal) 
Patient Reported Side Effect 0.648 0.438 - 0.958 Severity (4-point ordinal) 
Patient Satisfaction with 
1.028 1.014- 1.043 Physician (!-point) 
*Model II 
Patient Reported Treatment 2.963 1.988-4.415 
Effectiveness (5-point ordinal' 
Patient Reported Side Effect 0.651 0.432 - 0.981 Severity ( 4-point ordinal) 
Patient Satisfaction with 
1.029 1.013 - 1.045 Physician (!-point) 
IBS-SS (3-point ordinal) 0.636 0.378 - 1.069 
BSI (1 point 1.009 0.972- 1.047 
.. Model I IS based on logistic regressiOn model, each vanable adjusted for other variables listed and patient 
demographics (age, race, gender, and education); none were statistically significant (95% CI = NS) 
!Model II is based on logistic regression model; each variable adjusted for other variables listed and baseline 
symptom scales. 
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T bl 5 N a e onprescnptwn D rug 




Patient Reported Treatment 2.254 1.652- 3.076 
Effectiveness (5-point ordinal) 
Patient Reported Side Effect 0.712 0.535 - 0.948 Severity ( 4-point ordinal 
Patient Satisfaction with 
1.020 1.010-1.031 Physician (!-point) 
tModelll 
Patient Reported Treatment 2.087 1.530- 2.847 
Effectiveness (5-point ordinal) 
Patient Reported Side Effect 0.774 0.575 - 1.041 Severity ( 4-point ordinal) 
Patient Satisfaction with 
1.019 1.008 - 1.031 Physician (!-point) 
IBS-SS (3-point ordinal) 0.743 0.505 - 1.094 
BSI (1 point 0.988 0.961- 1.016 
.. Model I IS based on logistic regression model, each vanable adjusted for other variables listed and patient 
demographics (age, race, gender, and education); none were statistically significant (95% CI = NS) 
!Model II is based on logistic regression model; each variable adjusted for other variables listed and baseline 
symptom scales. 
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Adjusted todds Ratios Comparing Ordinal Response to Satisfaction with Treatment with 
Independent Variables . 
T bl 6 P a e . f D U rescnpnon rug sers 
Independent Variable Odds Ratio Confidence 
Interval 
tModell 
Patient Reported Treatment 11.892 7.590- 18.633 
Effectiveness (5-point ordinal) 
Patient Reported Side Effect 0.607 0.430 - 0.856 Severity ( 4-point ordinal) 
Patient Satisfaction with 
1.024 1.012- 1.036 Physician (!-point) 
*Model II 
Patient Reported Treatment 10.393 6.524 - 16.555 
Effectiveness (5-point ordinal) 
Patient Reported Side Effect 0.577 0.400 - 0.834 Severity ( 4-point ordinal) 
Patient Satisfaction with 
1.022 1.010- 1.035 Physician (!-point) 
IBS-SS (3-point ordinal 0.633 0.404 - 0.993 
BSI (l point 0.985 0.955- 1.016 
.. Model I IS based on ordmallogisllc regression model, each vanable adjusted for other variables listed and patient 
demographics (age, race, gender, and education); none were statistically significant (95% CI = NS) 
1Model II is based on ordinal logistic regression model; each variable adjusted for other variables listed and baseline 
symptom scales. 
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T bl 7 N a e onprescnptwn D U rug sers 
Independent Variable Odds Ratio Confidence 
Interval 
tModell 
Patient Reported Treatment 16.054 10.205 - 25.256 Effectiveness (5-point ordinal) 
Patient Reported Side Effect 
0.626 0.468 - 0.836 Severity ( 4-point ordinal) 
Patient Satisfaction with 
1.020 1.009 - 1.031 Physician (!-point) 
*Mode! II 
Patient Reported Treatment 18.040 11.078- 29.376 Effectiveness (5-point ordinal 
Patient Reported Side Effect 0.684 0.502 - 0.932 Severity ( 4-point ordinal) 
Patient Satisfaction with 
1.022 . 1.022 - 1.034 Physician (!-point) 
IBS-SS (3-point ordinal 1.188 0.796- 1.771 
BSI (1 point 0.983 0.956- 1.012 
.. Model I IS based on ordmallogistic regressiOn model, each variable adjusted for other variables listedand patient 
demographics(age, race, gender, and education); none were statistically significant (95% CI = NS) 
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